WinstonWınston
Back
Stock

Lincoln Pharmaceuticals

LINCOLN.BO
61
Drug Manufacturers - Specialty & Generic · Healthcare
Price
₹633.00
+14.00 (+2.26%)
Market Cap
₹12.73B
Exchange
Bombay Stock Exchange
Winston Score
61
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Sep 7, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Strong
Growth
Good
Cash Flow
Mixed
Stability
Good
Valuation
Good
Dividends
Good
Track this stock — start free trial

§Winston Score History

The full picture

Operating from its headquarters in Ahmedabad, India, Lincoln Pharmaceuticals Ltd. is a well-established Indian enterprise dedicated to the production and commercialization of a diverse range of pharmaceutical products. The company's extensive therapeutic portfolio addresses numerous health concerns, offering solutions across areas such as cold and cough relief, infectious disease management (antibiotics, antifungals, antimalarials), pain alleviation, gastrointestinal health, dermatology, anti-diabetic and anti-hypertensive medications, gynecological treatments, and formulations for cardiovascular, central nervous system, and respiratory conditions, alongside a selection of branded generic drugs. Furthermore, Lincoln Pharmaceuticals maintains a significant international footprint, exporting its pharmaceutical offerings to approximately 60 nations worldwide, encompassing key markets in Europe, Canada, North and Latin America, Africa, and the Asia Pacific region. This pharmaceutical firm was originally incorporated in 1979.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+30.8% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+30.9% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

₹0/ year

↓ Declining (-100% vs prior year)

0.0% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Cash Position

Cash flow positive

₹0 cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Lincoln Pharmaceuticals grew revenue 31% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 20.0M (2022) → 20.0M (2026)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
57.8%
Premium pricing power — 57.8% gross margin
Profit after running costs
Operating Margin
41.2%
Excellent — 41.2% operating margin
Return on the money invested
ROCE
19.3%
Strong — 19.3% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+14.0%
Fast-growing sales (+14.0% YoY)
Profit growth
EPS YoY
+11.7%
Earnings growing (+11.7% YoY)

Healthy double-digit earnings growth — what compounders look like.

How steady the profit is
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
52%
Weak — only 52% of profit becomes cash
Spare cash per sale
FCF Margin
5.4%
Thin free cash flow (5.4%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
181.71x
Comfortably covers interest (181.7x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
13.1x
Attractive valuation — P/E 13.1

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
0.28%
Small dividend — 0.28% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
+15.0%
Dividend growing fast (15.0% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial